Acutaas Chemicals Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 2682 as of 06 May 15:30 . The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Acutaas Chemicals Ltd for the Mar '26 is ₹ 443.86 crore as compare to the Dec '25 revenue of ₹ 397.88 crore. This represent the growth of 11.56% The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the decline of -100% The ebitda of Acutaas Chemicals Ltd for the Mar '26 is ₹ 194.62 crore as compare to the Dec '25 ebitda of ₹ 155.35 crore. This represent the growth of 25.28% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -100% The net profit of Acutaas Chemicals Ltd changed from ₹ 14.69 crore to ₹ 134.28 crore over 8 quarters. This represents a CAGR of 202.34% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Acutaas Chemicals Ltd

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India.
The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018.
The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies. The Company is engaged in business of drugs intermediate chemicals and related activities.
The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Acutaas Chemicals Ltd is 21,963 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 66,987 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd?

As of May 6, 2026, the Acutaas Chemicals Ltd stock price is INR ₹2682.65. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2373.75.

How do dividend payouts of Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.